POPULARITY
19 episodes with psychedelic studies maps
6 episodes with psychedelic studies maps
7 episodes with psychedelic studies maps
7 episodes with psychedelic studies maps
3 episodes with psychedelic studies maps
4 episodes with psychedelic studies maps
4 episodes with psychedelic studies maps
3 episodes with psychedelic studies maps
2 episodes with psychedelic studies maps
Rick Doblin, Ph.D., is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit established in 1986 to advance evidence-based psychedelic therapy and end prohibition. MAPS incubated Lykos Therapeutics (formerly MAPS Public Benefit Corporation) which is leading drug development of MDMA-assisted therapy for PTSD. Learn more about Psychedelic Science 2025, June 16–20 at the Colorado Convention Center in Denver, at www.psychedelicscience.org, and visit www.maps.org for information on MAPS Learn more about your ad choices. Visit podcastchoices.com/adchoices
Working with partners in government, business, and the community, MAPS Canada is committed to advancing psychedelic medicine by supporting scientific, multidisciplinary research; advocating for drug policy reform; offering public education; and supporting equitable access to legal and regulated psychedelic medicine in Canada. The Multidisciplinary Association for Psychedelic Studies (MAPS) was formed in the US in 1986, in response to the US Drug Enforcement Agency's classification of MDMA as Schedule 1 substance, and has been developing medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics since then. MAPS Canada was founded as a sister organization to MAPS in 2011, and is a registered Canadian non-profit organization. Based in Vancouver and with hundreds of volunteers from across Canada, MAPS Canada is moving forward to become the leading Canadian source of information, resources and advocacy regarding psychedelic medicine and related clinical research, education, and public policy. Learn More at https://mapscanada.org/about/ MAPS Canada is entirely funded by public donation and your support really makes a difference. Find out about all the ways you can support MAPS Canada's mission by visiting our donation link https://mapscanada.org/donate/ Many ways to engage, join our community: / mapscanada / mapscanada / mapscanada
Episode SummaryThe highly informed and deeply compassionate Amy Emerson joins Jef Szi and the How Humans Work Podcast for a remarkable conversation about the evolving landscape of psychedelics. With her extensive involvement and leadership in the Multidisciplinary Association of Psychedelic Studies (MAPS)* and their multi-year effort to get MDMA approved by FDA as a therapeutic medicine for PTSD. There are few better than Amy who can speak to the state of psychedelics for medical use in society. Not only does Amy share her honest appraisal about FDA drug approval process and members of congress on the Hill, she gives us the little known and fascinating history of MDMA. Some highlights are Sasha and Ann Shulgin's groundbreaking contributions, the reputational damage MDMA suffered in the 90's, the long-game efforts of Rick Doblin and others, the powerful way MDMA works on the brain, and the remarkable promise MDMA has shown to help people suffering with PTSD. Put together as a whole, Emerson offers us a destigmatized and inspiring view of MDMA beyond the common street descriptions of Ecstasy and Molly. From MDMA and the Medical Model, Amy then helps us see the many other use-cases for psychedelics that have a long and varied history. Building on issues of trauma and the importance of spiritually reconnecting with ourselves, we walk through the psychological benefits that can come with right-use of psychedelics.Finally, this conversation opens the visions of what future of psychedelic use in society through thoughtful contexts that track safety concerns and how, much like meditation, these ‘medicines' can have a place in our society like Buddhist and meditation practices have entered our culture. All in all, Breaking the Stigma is a podcast of significance, as it invites us to reconsider our biases around psychedelics at a time when our society is challenged by mental health matters like trauma and the pervasive disconnection from nature and spiritual renewal. ***** About: Amy Emerson is a highly respected leader in the field of psychedelic-assisted therapy. She was Lykos Therapeutics (formerly MAPS PBC) CEO for an important period in advancing MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) as a drug with the FDAShe earned a Bachelor of Science in Genetics and Cell Biology from Washington State University and spent the early career involved in roles at pharmaceutical companies, where she contributed to the development of therapies in immunology, oncology, and vaccines .In 2003, she began volunteering with the Multidisciplinary Association for Psychedelic Studies (MAPS), assisting with clinical research monitoring. Her expertise was instrumental in establishing MAPS' clinical department and managing the MDMA Clinical Development Program. When MAPS founded its Public Benefit Corporation (MAPS PBC) in 2014 to develop and commercialize MDMA-assisted therapy, Emerson was appointed CEO .Under her leadership, the organization, later rebranded as Lykos Therapeutics, completed multiple Phase 2 and Phase 3 clinical trials and raised approximately $150 million in funding. The company grew to over 120 employees, all working toward the goal of obtaining FDA approval for MDMA-assisted therapy for PTSD .Amy resigned form her CEO role in September 2024. Currently she is a senior advisor to Lykos and an independent psychedelic research consultant, awaiting the next big adventure.*****Chapters00:00 Introduction and Setting the Stage02:40 The Evolution of Psychedelic Research06:10 Understanding Stigma and Its Origins10:54 MDMA: From Therapy to Recreation16:33 Therapeutic Applications of MDMA20:28 Navigating the FDA and Drug Development24:45 Challenges
Ben "Doc" Askins is a multifaceted professional with a rich background in both military service and mental health care. He holds degrees in Outdoor Education, Intercultural Studies, Physician Assistant Studies, and a Master of Divinity. During his nearly two-decade military career, he practiced and taught wilderness, tactical, and expeditionary medicine. In his civilian role as a Psychiatric Physician Assistant, Ben adopts an integrative approach to mental health, specializing in ketamine-assisted psychotherapy, medication management, and spiritual direction. He is certified by the Multidisciplinary Association for Psychedelic Studies (MAPS) in MDMA-assisted psychotherapy. Ben is the author of "Anti-Hero's Journey: The Zero With a Thousand Faces," a book that serves as both a memoir and a philosophical exploration. The work challenges traditional narratives of the "hero's journey," offering readers a unique perspective on self-discovery and personal growth. In addition to his writing, Ben hosts the "Anti-Hero's Journey" podcast, where he engages in thought-provoking discussions on topics ranging from trauma and empathy to unconventional healing methods. His episodes often delve into the complexities of the human experience, providing listeners with insights into overcoming personal challenges. Ben's expertise in ketamine-assisted psychotherapy is a cornerstone of his practice. He has conducted numerous sessions focusing on treating depression, PTSD, and acute suicidality. His commitment to innovative mental health treatments is evident in his clinical work and ongoing research.
The breakthroughs we're seeing in psychedelic medicine today started with non-profit organizations taking risks that others wouldn't.Three organizations leading the charge are Multidisciplinary Association for Psychedelic Studies (MAPS), OPEN Foundation and Champalimaud Foundation.Psychedelic research faces unique hurdles, such as Schedule I drug classification, complex regulatory requirements, and historical stigma. Traditional funding sources (pharma, government and academia) often avoid these high-risk, long-term investments, which is where non-profits can make big strides. They tend to be mission-driven, patient-focused, and have a long-term commitment to research.Check out my latest Nina's Note to learn how these organizations push psychedelic research forward and act as bridge-builders between science and public understanding.
Dr. Rick Doblin, founder of Multidisciplinary Association for Psychedelic Studies (MAPS), and Jeff Zucker discuss activism, psychedelics, epigenetics, generational trauma, and more. Watch this episode on YouTube https://youtu.be/xlsVDPRvDtE Chapters: 0:00 - Intro 2:34 - People are the Answer 4:37 - Put it Into Practice 5:56 - Intention 10:24 - Fear and Motivation 12:05 - What Motivates You? 19:45 - How Relatives Coped with the Holocaust 24:36 - Epigenetics of Trauma 26:29 - Giving Back in Early Life 33:43 - Global Spirituality 39:49 - What Lead to Starting MAPS? 52:44 - How Do We Move Forward with MDMA? 57:08 - State Level an Option? 1:00:28 - MAPS Cannabis Project 1:02:18 - Medical Cannabis in SC 1:05:02 - How Do You Avoid Burnout? 1:07:18 - What is MAPS Working on Now? 1:11:04 - Oregon Recriminalization 1:13:17 - Snap Your Fingers 1:15:26 - How to Support Rick Doblin: https://www.linkedin.com/in/rickdoblin/ https://www.instagram.com/rickdoblinphd/ MAPS: https://maps.org/ https://www.linkedin.com/company/mapsnews/ https://www.instagram.com/maps__org/ https://www.facebook.com/mapsmdma https://twitter.com/MAPS https://www.youtube.com/c/mapsmdma https://www.reddit.com/user/MAPSPsychedelic/?rdt=36196 Host: Jeffrey M. Zucker Producer: Kait Grey Editor: Nick Case Recording date: 12/3/24
In this episode of the MindHack Podcast, we sit down with Ben "Doc" Askins, a former combat medic turned psychiatric physician assistant, who brings a wealth of experience in trauma therapy and unconventional healing. With nearly two decades in military medicine and a specialization in psychedelic-assisted psychotherapy, Ben challenges the traditional Hero's Journey narrative and instead explores the path of the Anti-Hero—a journey that delves into the raw, real, and often messy truths of self-discovery. Through his unique insights, Ben shares how confronting trauma and embracing empathy are essential for true healing.This conversation is for anyone grappling with their own inner battles or seeking to make peace with past traumas. Together, we uncover practical steps to break free from self-deception, build meaningful connections, and find empathy not only for others but also for ourselves. Join us as we unpack a new approach to healing—one that is unfiltered, authentic, and ultimately empowering. ℹ️ About this Guest Ben "Doc" Askins is a former combat medic and psychiatric physician assistant with nearly two decades of experience in trauma care and therapy. Certified in MDMA-assisted psychotherapy by the Multidisciplinary Association for Psychedelic Studies (MAPS), Ben blends traditional medicine with innovative approaches to healing. As the author of Anti-Hero's Journey: The Zero With a Thousand Faces, he challenges conventional narratives of growth, offering raw insights on trauma, empathy, and self-discovery. Through his work, Ben inspires others to confront their struggles and embrace authentic transformation.WebsiteClinical WebsiteFacebook PageYouTubeTwitterInstagramListen on Apple PodcastListen on SpotifyDownload as an MP3 - https://bit.ly/3B3UXKnAnti-Hero's Journey: The Zero With a Thousand Faces: A Warped War Memoir on the Way to Enlightenment By Ben "Doc" Askins
Ospite della 131° puntata di Illuminismo Psichedelico è Rick Doblin, fondatore e presidente della Multidisciplinary Association for Psychedelic Studies (MAPS) ed ex membro del consiglio di amministrazione di Lykos Therapeutics. Insieme a Doblin abbiamo parlato della sua scoperta e del suo rapporto con l'MDMA, di come questo abbia ispirato la nascita di MAPS e le ricerche per consentire un uso terapeutico della sostanza, ma anche di come poi le cose siano andate male, a causa della concorrenza di altre entità che chiedevano fondi per ricerche sugli psichedelici MAPS è stata costretta a generare una costola "for profit", Lykos, che ben presto è diventata un "lupo tra i lupi", e Doblin ha deciso di lasciarla, mostrandosi molto critico con come la nuova entità ha scelto di comunicare ma anche di difendere i risultati della fase 3 dei trial sull'MDMA, bocciati nella scorsa estate dalla FDA.
In this episode, Joe interviews Rick Doblin, Ph.D.: founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), and former board member at Lykos Therapeutics, MAPS' public benefit subsidiary. Doblin tells his side of the story: that the FDA's concerns with double blinding not working had been fully addressed ahead of time, that they had negotiated agreements that were no longer agreed to when new FDA employees came on board, that there was a lot of confusion from going back and forth with the FDA on how Phase 3 studies should be designed, and more. He believes that Lykos made a massive mistake in assuming that provable science was more important than public opinion, and that ignoring critics who were saying whatever they wanted caused them to lose control of the narrative – which clearly influenced the advisory committee. While Lykos figures out their next steps with the FDA, MAPS is focusing their attention on what they feel is most important in light of this ruling: better public education and drug policy. He talks about: How there's a bias at the FDA to be harsh: Does automatically saying no just make it look like you're being rigorous? The work of the Dutch government in researching MDMA, and Lykos' odd decision to not highlight any of it Massachusetts' Legalization and Regulation of Psychedelic Substances initiative, and the huge opportunity for progress at the local level Why federal agents at Burning Man work so hard to give tickets to attendees for smoking cannabis Why sharing stories of your positive experiences with psychedelics is so important and more! MAPS has announced that 2025's Psychedelic Science conference will be in Denver, June 16-20, and will have experiential opportunities before and after. For links, head to the show notes page.
Interested in working with Gina? www.ginagratza.comFollow her on Instagram @gina.gratza Gina Gratza is a licensed marriage and family therapist and has spent over a decade supporting individuals, couples, and families through the complexities of trauma, fractured relationships, and personal transformation. She specializes in psychedelic-assisted facilitation, deeply influenced by her work with individuals navigating trauma and eating disorders. Gina is certified in MDMA-Assisted Therapy for PTSD from the Multidisciplinary Association for Psychedelic Studies (MAPS). She is also a ketamine-assisted therapist, trained by the Polaris Insight Center. Gina helped launch the first legal Oregon psilocybin facilitator training school, InnerTrek, and served as Lead Educator and Program Coordinator. Gina is also engaged in psychedelic research with the Social Neuroscience and Psychotherapy Lab as a research study therapist supporting veterans with PTSD. Gina launched a new practice this year centered on women's empowerment. With a variety of group offerings online and in-person, Gina aims to create a community of women who can come together, grow, and heal in the connection. Her practice also supports those navigating and exploring psychedelic spaces. Gina is a seeker, a playful dancer, an embodied woman, and a poet. She continuously moves toward her authentic Self and loves engaging others interested in this dance.
Interested in working with Gina? www.ginagratza.comFollow her on Instagram @gina.gratza Gina Gratza is a licensed marriage and family therapist and has spent over a decade supporting individuals, couples, and families through the complexities of trauma, fractured relationships, and personal transformation. She specializes in psychedelic-assisted facilitation, deeply influenced by her work with individuals navigating trauma and eating disorders. Gina is certified in MDMA-Assisted Therapy for PTSD from the Multidisciplinary Association for Psychedelic Studies (MAPS). She is also a ketamine-assisted therapist, trained by the Polaris Insight Center. Gina helped launch the first legal Oregon psilocybin facilitator training school, InnerTrek, and served as Lead Educator and Program Coordinator. Gina is also engaged in psychedelic research with the Social Neuroscience and Psychotherapy Lab as a research study therapist supporting veterans with PTSD. Gina launched a new practice this year centered on women's empowerment. With a variety of group offerings online and in-person, Gina aims to create a community of women who can come together, grow, and heal in the connection. Her practice also supports those navigating and exploring psychedelic spaces. Gina is a seeker, a playful dancer, an embodied woman, and a poet. She continuously moves toward her authentic Self and loves engaging others interested in this dance.
Jill Sitnick's journey with PTSD began in her childhood, where she faced severe trauma due to an abusive father and a clinically depressed mother. Despite leaving her tumultuous home life at 19 and building a successful career in educational technology, the unresolved trauma from her past caught up with her in her late forties. After the passing of her long-term partner, Jill experienced severe PTSD attacks that left her feeling suicidal and constantly on high alert. After months of talk therapy without significant improvement, Jill's therapist suggested exploring MDMA-assisted therapy. MDMA, commonly known by its street names ecstasy or molly, is a synthesized chemical that has shown promising results in treating PTSD. Jill was initially skeptical but decided to give it a try after reviewing clinical trial data from the Multidisciplinary Association for Psychedelic Studies (MAPS). The results were nothing short of miraculous. MDMA helped Jill calm her body and mind, allowing her to confront and process her traumatic memories without the overwhelming fear and anxiety that typically accompanied them. Jill's story is a testament to the transformative power of psychedelic-assisted therapy and its potential to offer hope and healing to those suffering from PTSD. thejourneysage.com
Rick Doblin, Ph.D., is the Founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary's Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and puppy, with three empty rooms from his children who have all graduated college and begun their life journeys. Learn more about Rick by listening to his Origin Story and watching his TED Talk.
After much deliberation, this week a panel of experts advising the Food and Drug Administration voted against the approval of therapy-guided MDMA for treating PSTD. Kennedy criticizes the panel for prohibiting PSTD patients from getting effective treatment and highlights the success of studies and clinical trials conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS) and the high improvement rates reported by participants. Follow Kennedy on Twitter: @KennedyNation Kennedy Now Available on YouTube: https://bit.ly/4311mhD. Learn more about your ad choices. Visit megaphone.fm/adchoices
Dr. Eva Altobelli, MD is the founder of Home-LA. She is a diplomat of the American Board of Psychiatry and Neurology. Dr. Altobelli holds accreditation from the Multidisciplinary Association of Psychedelic Studies (MAPS) to administer MDMA-assisted therapy for PTSD. She has extensive experience in working with MDMA, psilocybin, and ketamine. Dr. Altobelli is committed to setting the highest standards of safety, ethics and efficacy. We discuss topics including: What is ketamine assisted therapy? Understanding professional assisted therapy/aka: “clinician experiential” Psychedelics can increase cognitive and emotional flexibility with eating disorder clients How these types of treatments can support personal and spiritual growth SHOW NOTES: www.home-la.com www.instagram.com/homela_drevaaltobelli ____________________________________________ If you have any questions regarding the topics discussed on this podcast, please reach out to Robyn directly via email: rlgrd@askaboutfood.com You can also connect with Robyn on social media by following her on Facebook, Instagram, Twitter, and LinkedIn. If you enjoyed this podcast, please leave a review on iTunes and subscribe. Visit Robyn's private practice website where you can subscribe to her free monthly insight newsletter, and receive your FREE GUIDE “Maximizing Your Time with Those Struggling with an Eating Disorder”. Your Recovery Resource, Robyn's new online course for navigating your loved one's eating disorder, is available now! For more information on Robyn's book “The Eating Disorder Trap”, please visit the Official "The Eating Disorder Trap" Website. “The Eating Disorder Trap” is also available for purchase on Amazon.
Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture. This week's episode is a crossover roundtable event with our friends at the Multidisciplinary Association for Psychedelic Studies (MAPS) covering the DEA's proposed rescheduling of cannabis from Schedule I to a Schedule III drug. Hosted by our very own Anne Donohoe, the Q&A discussion also features Betty Aldworth, Director of Communications & Post-Prohibition Strategy at MAPS, Karen O'Keefe, Director of State Policies at Marijuana Policy Project (MPP) and Paul Armentano, Deputy Director at NORML. With the unprecedented federal drug policy change on the near horizon, MAPS assembled leaders with more than 50 years of combined experience in the cannabis policy reform movement to talk about what these changes are, why they matter, what myths need debunking, and what still needs to be done. Some of the topics covered in this conversation include the impact rescheduling will have on research and development of cannabis-based medicines, criminal law and systems-impacted people, cannabis banking and interstate commerce and veteran affairs. If you are interested in learning more about how MAPS, MPP or NORML have played pivotal roles in implementing drug policy reform over the decades, be sure to follow them all on their socials linked in our show notes and visit their websites to follow their advocacy work. So, sit back and enjoy this crossover Q&A discussion on the future of cannabis drug policy. Links and mentions in the show https://maps.org/ https://norml.org/ https://www.mpp.org/ Links to the guest's company and social media accounts Betty Aldworth LinkedIn: https://www.linkedin.com/in/bettyaldworth/ Karen O'Keefe LinkedIn: https://www.linkedin.com/in/karen-o-keefe-255a9921a/ NORML LinkedIn: https://www.linkedin.com/company/norml/ MPP Twitter: https://twitter.com/marijuanapolicy NORML Twitter: https://twitter.com/NORML MAPS Twitter: https://twitter.com/maps Show Credits: This episode was hosted by Anne Donohoe of KCSA Strategic Communications. Special thanks to our Program Director, Shea Gunther and to the MAPS team. You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels: X: @KCSAPodcastLabs Instagram: @KCSAPodcastLabs LinkedIn: linkedin.com/company/thegreenrushpodcast
The U.S. Food and Drug Administration is reviewing MDMA-assisted therapy for post-traumatic stress disorder, which could become the first psychedelic-assisted therapy as early as August. Today, The Common presents the final episode of our three-part series looking at the past, present and future of psychedelics in Massachusetts as a potential ballot question that could lead to the decriminalization of natural psychedelic substances in Massachusetts. Rick Doblin, founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), is featured in today's conversation. He has led efforts to bring psychedelics back into mainstream medicine, in part by organizing clinical drug trials to get MDMA-assisted therapy for PTSD approved by the FDA. Greater Boston's daily podcast where news and culture meet.
In this episode, Joe interviews Devon Phillips: community & partnerships officer for the Multidisciplinary Association for Psychedelic Studies (MAPS). Phillips works on strategies to tackle the questions: How do we responsibly mainstream psychedelics? And how do we get culture engaged? He's focusing on being the bridge to psychedelics outside of research, facilitating workshops and psychedelic coming-out stories at music festivals and conferences. He talks about harm reduction and drug checking at festivals, the concept of training big names to become trustworthy resources, the differences found in a hop hop crowd compared to EDM, and the power in using psychedelics for pleasure and celebration – not just healing and growth. He also discusses: MAPS' involvement with the NFL for their 'My Cause, My Cleats' campaign, and how the San Francisco 49ers' Jon Feliciano is bringing awareness to psychedelic healing Details about MAPS' first responders training, fiscal sponsorship program, international therapist education program, and upcoming membership program (launching in June) The success of MAPS' Psychedelic Science and his hopes for the 2024 edition, taking place June 16 - 20 at the Denver Convention Center Dr. Carl Hart, drug exceptionalism, and the importance of creating safe containers and inclusive drug policy and more! For links and more, head to the show notes page.
Rick Doblin, founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), chats with Trey Elling. Topics include the potential medicinal benefits of... Intro (0:00) Cannabis (2:16) MDMA (9:55) Ibogaine (24:56) Psilocybin (31:56) Qualified psychedelic therapists (37:32) Total eclipses (42:39)
Jane talks with Ashley about expanding understanding and authentic spiritual connection through working with 5-MeO-DMT In this conversation, Jane and Ashley discuss the difference between 5-MeO DMT and NNDMT, as well as their personal experiences with 5-MeO DMT. They explore the profoundness of the experience and its impact on fear and the relationship with death. They also discuss the importance of making space for integration after the experience and the value of love, courage, and compassion. Ashley shares her perspective on reclaiming the word 'God' and the future of 5-MeO DMT in the context of psychedelic community churches. They emphasize the importance of finding a trained facilitator and the role of community in the psychedelic journey. Takeaways 5-MeO DMT and NNDMT (found in Ayahuasca) offer different experiences, with 5-MeO DMT often leading to more mystical and profound experiences. The 5-MeO DMT experience can have a transformative impact on fear and the relationship with death, leading to a greater sense of courage and acceptance. Integration is a crucial part of the psychedelic journey, and it is important to create space and seek support for the integration process. Finding a trained and experienced facilitator is essential for a safe and meaningful 5-MeO DMT experience. The future of 5-MeO DMT may involve the creation of psychedelic community churches, providing a safe and supportive environment for psychedelic experiences. Chapters 00:00 Introduction and Background Noise 00:42 Difference Between 5-MeO DMT and NNDMT 01:10 Ashley's Personal Experience with 5-MeO DMT 03:22 The Profoundness of the Experience 04:44 Impact on Fear and Relationship with Death 05:15 Transformation of Fear of Heights 06:13 Change in Perception and Relationship with Death 07:37 The Meaning of Life and Existential Questions 09:11 The Value of Love, Courage, and Compassion 10:23 Connecting with the Foundational Frequency of the Universe 11:24 The Importance of Making Space After the Experience 13:10 Reclaiming the Word 'God' J. Ashley T. Booth is a Licensed Clinical Social Worker in practice offering ketamine-assisted psychotherapy in Los Angeles, California. Since 2013, she's been a passionate educator and advocate surrounding the mindful use of psychedelics for healing, self-reflection, and the celebration of life as the founder of the Southern California psychedelic society, the Aware Project. 5-MeO-DMT has been the catalyst for her journey, leading her to be a psychospiritual retreat leader in Mexico where she facilitated 5-MeO-DMT and ibogaine. Her background in research led her to be a co-investigator on the Multidisciplinary Association of Psychedelic Studies (MAPS)-sponsored clinical trial of MDMA-assisted psychotherapy for the treatment of PTSD. Trained in psilocybin-assisted psychotherapy with Compass and a consultant with Beckley Psytech on their therapist training manual for the clinical use of 5-MeO-DMT in depression treatment, she is at the forefront of psychedelic research and therapy. She has collaborated with the Conclave (www.theconclave.info), actively promoting the ethical facilitation of 5-MeO-DMT sessions. Currently, she serves as a trainer and consultant in the intersection of psychedelic psychotherapy and spirituality. Her vision is grounded in the belief that the mindful reintegration of psychedelics into Western society fosters collective healing and cultivates a kinder world. www.ashleybooth.net Learn more about your ad choices. Visit podcastchoices.com/adchoices
Rick Doblin, Ph.D., is the Founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary's Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and puppy, with three empty rooms from his children who have all graduated college and begun their life journeys. Learn more about Rick by listening to his Origin Story and watching his TED Talk.MAPS Texas Eclipse InfoDonate to MAPS.orgThe JRE Episode that started it all.The Synergy of Medicine, Science, and Public Benefit.Lykos TherapeuticsBook: Zen and the Art of Motorcycle Maintenance
In today's episode of the Psychedelic Therapy Frontiers, the podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Rick Doblin, Ph.D. Rick is the Founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS). His tireless efforts over almost 40 years in both clinical research and public policy reform have played a key role in bringing psychedelic medicine to the very exciting point that it is now. They discuss the origin story behind MAPS, the existential crisis humanity is facing and the need for healing on a global scale, the potential FDA approval of MDMA-assisted therapy for PTSD, the “Fallen Mormon” study on the safety of MDMA, the “high bar” that should be set for therapists who work with psychedelic tools, whether or not those therapists should have their own psychedelic experiences as part of their training, and much more.https://maps.org/https://seetexaseclipse.com/Learn more about our podcast at https://numinus.com/podcast/Learn more about psychedelic therapy training opportunities at https://numinus.com/training/Learn more about our clinical trials at https://www.numinus.com/clinical-trials Learn more about Numinus at https://numinus.com/Email us at ptfpodcast@numinus.com Follow us on Instagram: https://www.instagram.com/drstevethayer/https://www.instagram.com/innerspacedoctor/https://www.instagram.com/numinushealth/
Today’s episode is with Rick Doblin Ph.D., the Founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. He founded MAPS in 1986, and currently resides in Boston with his wife and puppy, with three empty rooms from his children who have all graduated college and begun their life journeys. Learn more about Rick by listening to his Origin Story and watching his TED Talk. We talk about the following and so much more: ✅ Why he thinks psychedelics and plant medicine are important? ✅ His perspective on the spiritual connection to plant medicine and psychedelics and whether there is a difference if it comes from nature or if it's from a lab ✅ What is MAPS, and what is the mission of MAPS? ✅ How he navigates the challenges of destigmatizing these substances and promoting their potential therapeutic benefits ✅What his thoughts are on the different types of psychedelics – and if there are any that he prefers for some scenarios over others ✅ His thoughts on your 2019 TED talk, “The future of psychedelic-assisted therapy” and if your perspective changed at all post-pandemic? ✅ The experiment on the use of ayahuasca / MDMA between Jews and Arabs, and what the outcome was like If you’d like to join the waitlist for my next coaching program, sign up @ www.InnerKnowingSchool.com Please tag us and tell us what you loved! You can follow @Gateways_To_Awakening on Instagram or Facebook if you’d like to stay connected.
Welcome back to The Trip Report Podcast, a production of Beckley Waves, a Psychedelic Venture Studio.Today, I am speaking with Rick Doblin, founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS).December of last year was a milestone for Doblin and MAPS, as the organization submitted a New Drug Application for MDMA Assisted Therapy to the United States Food and Drug Administration.Then, in the first week of January, the MAPS Public Benefit Corp announced its rebranding to Lykos Therapeutics and a $100 million Series A financing.Needless to say, it has been a pivotal period in the organization's history and a watershed moment for the revival of psychedelic medicine, science, and policy.In February, the FDA accepted the application and granted a priority review, putting the decision timeline at August of this year.That's just around the corner.And so much is still up in the air—of course the big question—will the FDA grant approval? But also so many granular details that will have significant downstream effects on the commercial rollout, access, and cost.* What language will be on the drug label? * What will the Risk Evaluation and Mitigation Strategy entail? * How will patients be able to access the drug? * What will the FDA say about the role of therapy?Among others.So, I wanted to sit down with Rick to talk about it and get his perspective on the organization's evolution, the path ahead, and, most importantly, the many uncertainties that hang in the balance.In this conversation, we discuss:* The importance of therapy in conjunction with MDMA (and his loathing of the acronym MDMA-AT)* The many regulatory and bureaucratic details that go into the FDA's decision and subsequent commercial rollout, including:* Drug labeling* Therapist credentialing * Risk Evaluation and Mitigation Strategies* The negotiations he's led with the FDA over the last 20 years* Lykos' goal of getting MDMA-Assisted Therapy FDA approved and MAPS' goal of getting MDMA federally legalized* The role of therapist's first-hand experience with MDMA and the regulatory battle of ensuring legal access to this group* His future humanitarian and scientific plansAnd much more.And now I bring you my conversation with Rick Doblin.Listen to the episode on Substack, Spotify, Google or Apple.Credits:* Hosted by Zach Haigney * Produced by Zach Haigney, Erin Greenhouse, and Katelin Jabbari* Find us at thetripreport.com* Follow us on Instagram, Twitter, LinkedIn and YouTubeTheme music by MANCHO Sounds, Mixed and Mastered by Rollin Weary This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thetripreport.com
Host Jimmy Nguyen and is joined by special guest Steven Huang of the Multidisciplinary Association of Psychedelic Studies (MAPS), as they delve into the importance of sharing one's psychedelic experiences. Steven and Jimmy explore the parallels between coming out narratives in the LGBTQ+ community and sharing psychedelic experiences. Steven's personal journey, highlighted by his experiences as a queer Chinese American, adds a poignant layer to the discussion.Jimmy and Steven's dynamic exchange provides a roadmap for listeners contemplating sharing their own psychedelic stories, emphasizing the role of privilege, accessibility, and ethical responsibility, while stressing the importance of sensitivity, consent, and considering the audience and purpose behind sharing, whether it's for personal catharsis, connection, or advocacy. They discuss the challenges of navigating conversations in different settings, from intimate one-on-one discussions to casual social interactions or even professional environments like the workplace. They also touch on the delicate balance between authenticity and performance, cautioning against oversimplifying or sensationalizing experiences for the sake of storytelling. Throughout the episode, they encourage listeners to reflect on their motivations, intentions, and the broader societal context when sharing psychedelic narratives.No mushroom source? No problem. Download our Free Psilocybin Sourcing Guide.Additional Resources:Episode Blog PostYou Are Not Alone: Coming out of the Psychedelic ClosetHow to Ask Friends & Family for Psychedelic Therapy Support10 Best Tips For Supporting Loved Ones in Psychedelic TherapyTake your psychedelic education to the next level: Shop for Exclusive Client Resources.More Psychedelic Passage:Official WebsiteBook a ConsultationBlog PageYoutubeInstagram: @psychedelicpassage Reddit: u/psychedelicpassage
Ben Askins joins the VinnyRoc Podcast as a guest, bringing with him an eclectic and impressive background. He holds degrees in Outdoor Education, Intercultural Studies, Physician Assistant Studies, and Divinity. With nearly two decades of experience, he has practiced and taught wilderness, tactical, and expeditionary medicine in the military. In his civilian life, he is a Psychiatric Physician Assistant, known for his evidence-focused and integrative approach to mental health. This includes extensive experience in ketamine-assisted psychotherapy, medicine management, and spiritual direction. Ben is certified with the Multidisciplinary Association on Psychedelic Studies (MAPS) in MDMA-assisted psychotherapy. As a member of the Wilderness Medical Society, a National Outdoor Leadership School alum, and a veteran of the Global War on Terrorism, Ben's experiences are diverse and influential. His postgraduate training in Neuropsychiatry and Genomics further enhances his expertise, making him a unique and insightful voice in the fields of mental health and medicine. #KetamineForDepression #MDMAForPTSD #integrativemedicine #MentalHealthMatters #MindBodySpirit #HealingJourney #Transformation #Microdosing #PlantMedicine #PsychedelicRevolution #futureofmedicine We extend our sincere gratitude to our sponsors for their unwavering support of the VinnyRoc Podcast. Their commitment enables us to deliver content that informs, educates, and engages consistently. · Core Medical Group: Striving to pioneer wellness solutions and help you achieve optimal well-being. Visit https://www.coremedicalgrp.com to discover more. · GMR Gold: Offering premium gold and silver investment options to elevate your wealth. Explore more at https://www.gmrgold.com. · Everest: The ultimate marketplace for the great outdoors. Embark on your adventure today at https://www.everest.com. · Modern Gun School: Dedicated to enriching your firearms knowledge with a comprehensive curriculum. Find out more at https://mgs.edu. We value the contribution of each sponsor and appreciate their dedication to our shared goals. For those who haven't yet, we invite you to watch our latest episode on YouTube, subscribe to our channel, and follow us on social media to stay updated on upcoming content. If you find our discussions valuable, please share them within your networks. Thank you for your continued support of the VinnyRoc Podcast. #VinnyRocPodcast #ThankYouSponsors
This episode is brought to you by BiOptimizers Magnesium Breakthrough and Calm. Many people are unaware of the benefits of psychedelics when taken in a controlled, clinical setting under the care of a professional. Emerging research has shown promise for healing from trauma, connecting to your partner, and gaining insight into the bigger picture of consciousness and life itself. This week on The Dhru Purohit Podcast, Dhru sits down with Rick Doblin, Ph.D., the founder and President of the Multidisciplinary Association for Psychedelics (MAPS), to discuss the use of psychedelics, specifically MDMA, as a therapeutic intervention for qualifying candidates with complex mental illness, schizophrenia, PTSD, anxiety, eating disorders, and more. Rick Doblin, Ph.D., is the Founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on regulating the medical uses of psychedelics and marijuana and his Master's thesis on smoked marijuana vs. the oral THC pill in nausea control for cancer patients. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana as prescription medicines, for the personal growth of otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. In this episode, Dhru and Rick dive into (audio version / Apple Subscriber version):-Why it's so hard to see beyond existence (1:28 / 1:28)-How Rick's beliefs and personal views were shaped by his psychedelic experiences (8:19 / 6:58)-Potential sources of inner wisdom/guidance when taking psilocybin (16:07 / 14:30)-Idiosyncrasies that caused Rick to pursue psychedelic research (28:50 / 26:42)-A deep dive into the history of MDMA (35:03 / 32:06)-Therapeutic uses of MDMA (54:20 / 57:51)-The effects of psilocybin on the brain (1:10:45 / 1:07:46)-The war on drugs and how it impacted the public's perception of psychedelics (1:20:33 / 1:17:32)-The recent advancements in psilocybin and MDMA for therapeutic use (1:27:20 / 1:24:25)-Early evidence on the ill effects of marijuana: should we be concerned? (1:30:55 / 1:28:05)-Current status of MDMA in psychological interventions (1:42 / 1:39:24)-Future hopes for FDA to allow psychedelic drugs to come to market (1:45:22 / 1:42:04)Also mentioned in this episode:-Maui Wild Fires Support/Resources-Make a donation to MAPS here -Maps.orgFor more on Rick Doblin, follow him on Instagram @rickdoblinphd.BiOptimizers is offering 10% off + special gift with purchase, just head over to magbreakthrough.com/dhru with code DHRU10.Calm is offering an exclusive offer of 40% off a Calm Premium Subscription. Head over to calm.com/dhru today. Hosted on Acast. See acast.com/privacy for more information.
Rick is the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS) and has spent more than 30 years supporting psychedelic advancements. In this episode, he shares insights into his trailblazing journey and some of the exciting developments that are currently unfolding. For more information on The Great Mother's products, check out TheGreat.Mother on Instagram Check out our newly updated page instagram.com/positive_head Care to play a game with the youniverse? Ask the universe the episode you would most benefit from hearing next and click positivehead.com/game. Download The Golden Key audio or e-book at GoldenKey.Gift with the Code: POSITIVEHEAD Text Brandon to receive regular golden nuggets of wisdom at 310.564.0750
Rick Doblin, Ph.D., is the Founder & President of the Multidisciplinary Association for Psychedelic Studies (MAPS) and this episode is all about his life and work. This episode is a holistic look at the point where traditional therapy meets psychedelics and how Doblin and his team have spent the last few decades appealing to the scientific community and lawmakers across the world. Doblin gives us a fresh perspective on the mental health crisis discusses his studies & experiments in Iceland. We cover his early professional life and what lead him to pursue the science of alternative medicines. Doblin believes that with psychedelic assisted therapy, the world could be trauma free by 2070. Rick Doblin Links: MAPS - https://maps.org/about-maps/mission/ Get Involved - https://maps.org/take-action/ Instagram - https://www.instagram.com/rickdoblinphd/ Learn More - https://sprout.link/rickdoblinphd Please leave us a review on Apple & Spotify Podcasts. Vigilance Elite/Shawn Ryan Links: Website | Patreon | TikTok | Instagram Learn more about your ad choices. Visit podcastchoices.com/adchoices
This episode is brought to you by Rupa Health, InsideTracker, and LMNT.Compounds that have long been considered recreational drugs by conventional standards are finally being recognized through science as powerful tools for overcoming hard-to-treat health issues like PTSD, depression, addiction, and more. For the right person, psychedelics can provide a sense of peace and hope that helps heal their inner wounds and allows them to live with more freedom.In today's episode, I talk with Rick Doblin, Alberto Villoldo, and Wade Davis about the ancient healing mechanisms of plant medicine.Rick Doblin, PhD, is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in public policy from Harvard's Kennedy School of Government. His professional goals are to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist.Medical anthropologist Alberto Villoldo, PhD, is an international bestselling author who has researched the shamanic healing practices of the Amazon and Andes for over 25 years. He is the founder of the Four Winds Society, an organization dedicated to the bridging of ancient shamanic traditions with modern medicine and psychology.Wade Davis is a writer, photographer, and filmmaker. Explorer-in-Residence at the National Geographic Society from 2000 to 2013, he is currently Professor of Anthropology and the BC Leadership Chair in Cultures and Ecosystems at Risk at the University of British Columbia. He is the author of 23 books, including One River, The Wayfinders, and Into the Silence, and he was the winner of the 2012 Baillie Gifford Prize for Non-Fiction (formerly the Samuel Johnson Prize), the top nonfiction prize in the English language.This episode is brought to you by Rupa Health, InsideTracker, and LMNT. Rupa Health is a place where Functional Medicine practitioners can access more than 3,000 specialty lab tests like DUTCH, Vibrant America, Genova, and Great Plains. You can check out a free, live demo with a Q&A or create an account at RupaHealth.com.InsideTracker is offering my community 20% off at insidetracker.com/drhyman.LMNT is offering my listeners a free sample pack with any purchase. Get yours at DrinkLMNT.com/hyman today.Full-length episodes of these interviews can be found here:Rick DoblinAlberto VilloldoWade Davis Hosted on Acast. See acast.com/privacy for more information.
Rick Doblin, Ph.D., is the Founder in 1986 and President of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit that wholly owns its pharmaceutical arm, MAPS Public Benefit Corporation (PBC), which has completed two highly successful Phase 3 studies of MDMA-assisted therapy for PTSD. MAPS PBC stands at a crossroads between obtaining the additional resources it needs from philanthropy, ensuring public benefit is foremost, or becoming a publicly traded company. maps.org
© 2020-2025 Ivy Podcast Discovery LLC
